

A REVIEW ON Targeted Protein Elimination: Mechanisms, Therapeutic Modalities, and Clinical Progress

Dr.M.Lakshmi Prasanna, Eathakoti.vandana, Vasamsetty.Nithya

mallika,Yepuganti.BhavaniSrikari,Veerathi.Anantha Lakshmi,Veerathi.Mrudula, Dr.N.V.V.
Jagan Mohan Reddy,Dr.D.Narendra.

Vj's College of Pharmacy ,Affiliated by Andhra University,
Diwancheruvu,Rajamahendravaram.

ABSTRACT:

Targeted Protein Degradation (TPD) is a novel drug discovery approach that removes disease-causing proteins rather than simply inhibiting their activity. It utilizes the cell's natural degradation systems, mainly the ubiquitin-proteasome system and lysosomal pathways, to selectively eliminate target proteins. Key TPD technologies include Proteolysis Targeting Chimeras (PROTACs) and molecular glues, which direct unwanted proteins toward degradation. This approach enables the targeting of previously undruggable proteins and may provide longer-lasting therapeutic effects than conventional inhibitors. TPD has shown promising applications in cancer, neurodegenerative, autoimmune, and inflammatory diseases. Although challenges such as drug design, bioavailability, and resistance remain, ongoing research and clinical trials continue to advance the field. Overall, TPD represents a promising therapeutic strategy with the potential to transform modern drug development and disease treatment.

Keywords: Targeted Protein Elimination, Targeted Protein Degradation, PROTACs, Molecular Glues, Ubiquitin-Proteasome System, E3 Ubiquitin Ligases, Selective Protein Degradation, Lysosome-Targeting Chimeras (LYTACs), Autophagy-Targeting Chimeras (AUTACs), Proteasomal Degradation, Protein Homeostasis, Drug Discovery, Precision Medicine, Undruggable Targets, Therapeutic Protein Elimination, Clinical Development

1. INTRODUCTION :

The development of modern therapeutics has largely relied on small-molecule inhibitors and monoclonal antibodies that modulate the activity of disease-associated proteins. Although these approaches have achieved considerable clinical success, they are often limited by incomplete target inhibition, dose-dependent toxicity, and the emergence of drug resistance. Furthermore, a substantial proportion of the human proteome lacks suitable binding pockets for conventional drugs, rendering many disease-causing proteins “undruggable.” These limitations have prompted the search for innovative therapeutic strategies capable of directly eliminating pathogenic proteins rather than merely suppressing their activity [1,2].

Targeted Protein Elimination (TPE), also referred to as Targeted Protein Degradation (TPD), has emerged as a revolutionary approach in drug discovery. Unlike traditional inhibitors that require continuous occupancy of a target protein, TPE utilizes the cell's natural protein quality-control systems to selectively remove disease-associated proteins from the intracellular environment. This strategy results in sustained therapeutic effects and has the potential to overcome many limitations associated with conventional pharmacological interventions [3,4].

The concept of targeted protein elimination originated from studies of the ubiquitin-proteasome system (UPS), a highly regulated pathway responsible for maintaining cellular protein homeostasis. The UPS controls

protein turnover through the attachment of ubiquitin molecules to target proteins, marking them for degradation by the proteasome. Researchers recognized that artificially directing disease-causing proteins toward this degradation machinery could provide a powerful means of therapeutic intervention. This concept led to the development of Proteolysis-Targeting Chimeras (PROTACs), which represent one of the most successful and widely investigated TPE platforms [5,6].



In recent years, the field has expanded beyond PROTACs to include diverse degradation modalities such as molecular glues, lysosome-targeting chimeras (LYTACs), autophagytargeting chimeras (AUTACs), autophagosome-tethering compounds (ATTECs), and antibody-based degraders. These technologies exploit different cellular degradation pathways and enable the elimination of extracellular, membrane-bound, and intracellular proteins that were previously inaccessible to conventional therapeutics [7,8].

One of the most significant advantages of TPE is its catalytic mode of action. A single degrader molecule can repeatedly induce the degradation of multiple target protein molecules, resulting in enhanced potency and prolonged pharmacological effects. Moreover, because the target protein is physically removed from the cell, both enzymatic and nonenzymatic functions can be abolished, offering therapeutic benefits that cannot be achieved

through inhibition alone [9,10].

The potential applications of TPE extend across numerous disease areas, including cancer, neurodegenerative disorders, autoimmune diseases, infectious diseases, and metabolic disorders. Several degrader molecules have progressed into clinical trials, demonstrating encouraging efficacy and safety profiles. These developments highlight the growing importance of TPE as a next-generation therapeutic platform with the capacity to reshape modern medicine [11,12].

Despite remarkable progress, challenges remain in optimizing degrader design, improving tissue specificity, enhancing pharmacokinetic properties, and minimizing off-target effects. Advances in structural biology, computational chemistry, artificial intelligence, and medicinal chemistry are expected to accelerate the development of more effective and selective

degraders in the coming years [13,14].

Consequently, targeted protein elimination represents a paradigm shift in therapeutic development, offering novel opportunities to address previously intractable diseases and expand the boundaries of druggable targets. The continued evolution of degrader technologies is likely to play a central role in the future of precision medicine and drug discovery [15].

2. FUNDAMENTALS OF TPE

2.1 Definition and Concept of Targeted Protein Elimination

Targeted Protein Elimination (TPE) is an emerging therapeutic strategy that selectively removes disease-causing proteins from cells by exploiting endogenous protein degradation pathways. Unlike conventional inhibitors, which merely suppress protein activity, TPE promotes the complete destruction of target proteins, thereby eliminating both their enzymatic and non-enzymatic functions. This approach has attracted considerable attention because it can target proteins previously considered undruggable and can provide prolonged therapeutic effects through catalytic mechanisms [16,17].

The central principle of TPE involves the recruitment of a target protein to cellular degradation machinery, resulting in its recognition, ubiquitination, and subsequent degradation. Various technologies have been developed to achieve this goal, including PROTACs, molecular glues, LYTACs, AUTACs, and ATTECs. These platforms differ in their mechanisms but share the common objective of selectively eliminating pathogenic proteins to restore normal cellular function [18,19].

2.2 Cellular Protein Homeostasis

Cellular protein homeostasis, commonly referred to as proteostasis, is essential for maintaining normal cellular functions. Proteostasis encompasses the synthesis, folding, trafficking, and degradation of proteins within the cell. A delicate balance between protein production and degradation ensures that damaged, misfolded, or excess proteins do not accumulate and disrupt cellular processes [20].

Multiple quality-control systems operate within cells to regulate proteostasis. Molecular chaperones assist in protein folding, while degradation pathways remove proteins that are no longer needed or have become dysfunctional. Dysregulation of proteostasis has been implicated in numerous diseases, including cancer, neurodegenerative disorders, autoimmune diseases, and metabolic syndromes [21].

Protein degradation is therefore not merely a waste-disposal mechanism but a highly regulated process that controls signaling pathways, cell-cycle progression, gene expression, immune responses, and apoptosis. The ability to manipulate these degradation pathways therapeutically forms the foundation of targeted protein elimination technologies [22,23].

2.3 Ubiquitin–Proteasome System (UPS)

The ubiquitin–proteasome system (UPS) is the primary intracellular pathway responsible for selective degradation of short-lived and regulatory proteins. It plays a crucial role in maintaining cellular homeostasis and regulating diverse biological processes [24].

The UPS operates through the attachment of ubiquitin, a highly conserved 76-amino-acid protein, to target proteins. This process involves three classes of enzymes: ubiquitinactivating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). E1 enzymes activate ubiquitin in an ATP-dependent manner, E2 enzymes transfer activated ubiquitin, and E3 ligases confer substrate specificity by recognizing target proteins [25].

Following polyubiquitination, the tagged protein is recognized by the 26S proteasome, a large multicatalytic complex composed of a 20S catalytic core and two 19S regulatory particles. The proteasome unfolds and degrades the target protein into short peptides, while ubiquitin molecules are recycled for subsequent degradation cycles [26].

The UPS is particularly attractive for therapeutic manipulation because more than 600 E3 ligases exist in the human genome, providing numerous opportunities for selective target engagement. Most PROTACs and molecular glues exploit E3 ligases such as cereblon (CRBN), von Hippel–Lindau (VHL), mouse double

minute 2 (MDM2), and inhibitor of apoptosis proteins (IAPs) to induce degradation of disease-associated proteins [27,28].

Recent advances in structural biology have improved understanding of E3 ligase–substrate interactions, facilitating the rational design of highly selective degraders. These discoveries have significantly accelerated the development of TPE-based therapeutics for various diseases [29].

2.4 Lysosomal Degradation Pathways

In addition to the UPS, lysosomal degradation represents another important pathway exploited in targeted protein elimination. Lysosomes are membrane-bound organelles containing hydrolytic enzymes capable of degrading proteins, lipids, nucleic acids, and damaged organelles [30].

Unlike the proteasome, which primarily degrades intracellular proteins, lysosomes can process extracellular proteins, membrane-associated proteins, protein aggregates, and large macromolecular complexes. This broader substrate range makes lysosomal pathways particularly useful for targeting proteins inaccessible to proteasomal degradation [31].

Three major lysosomal degradation mechanisms have been identified: macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy involves the formation of double-membrane vesicles known as autophagosomes that engulf cellular cargo and subsequently fuse with lysosomes for degradation. Microautophagy occurs through direct invagination of lysosomal membranes, whereas chaperone-mediated autophagy selectively transports proteins across the lysosomal membrane [32,33].

Emerging degrader technologies such as LYTACs, AUTACs, and ATTECs exploit lysosomal pathways to eliminate extracellular proteins, membrane proteins, and protein aggregates. These approaches expand the range of therapeutic targets beyond those accessible through the UPS alone and offer promising opportunities for treating neurodegenerative diseases and other proteinopathies [34].

The integration of proteasomal and lysosomal degradation strategies has greatly broadened the scope of targeted protein elimination. By harnessing both intracellular degradation systems, researchers can design therapies capable of selectively removing a diverse array of pathogenic proteins with high precision and efficacy [35].

3. MECHANISMS OF TARGETED PROTEIN ELIMINATION

Targeted Protein Elimination (TPE) utilizes the cell's endogenous degradation machinery to selectively remove disease-associated proteins. The success of this strategy depends on precise molecular mechanisms that enable recognition, tagging, and destruction of target proteins. Most current TPE approaches exploit either the ubiquitin–proteasome system (UPS) or lysosomal degradation pathways to achieve selective protein elimination [36,37].

3.1 Ubiquitination Process

Ubiquitination is a post-translational modification in which ubiquitin molecules are covalently attached to a target protein. This process serves as a cellular signal for protein degradation and regulates numerous biological functions including cell-cycle progression, DNA repair, signal transduction, and immune responses [38].

The ubiquitination cascade begins with activation of ubiquitin by an E1 ubiquitin-activating enzyme in an ATP-dependent reaction. Activated ubiquitin is then transferred to an E2 ubiquitin-conjugating enzyme. Finally, an E3 ubiquitin ligase facilitates the transfer of ubiquitin from the E2 enzyme to lysine residues on the target protein. Repeated rounds of ubiquitin attachment generate polyubiquitin chains that serve as degradation signals for the proteasome [39].

In targeted protein elimination, degraders such as PROTACs induce the formation of a ternary complex between the target protein and an E3 ligase. This proximity promotes efficient ubiquitination of the target protein, leading to its recognition and degradation by the proteasome [40].

3.2 Role of E1, E2, and E3 Enzymes


The ubiquitination process relies on the coordinated activity of E1, E2, and E3 enzymes. E1 enzymes initiate the pathway by activating ubiquitin molecules through ATP hydrolysis. Only two major E1 enzymes are responsible for ubiquitin activation in humans, highlighting their fundamental role in cellular protein turnover [41].

E2 enzymes receive activated ubiquitin from E1 enzymes and function as intermediaries in the transfer process. Approximately 40 E2 enzymes have been identified in humans, each exhibiting varying substrate preferences and interactions with E3 ligases [42].

E3 ligases provide substrate specificity and represent the most important component of targeted protein elimination technologies. More than 600 E3 ligases have been identified in the human genome, enabling selective recognition of a vast array of protein substrates. Commonly used E3 ligases in degrader design include cereblon (CRBN), von Hippel–Lindau (VHL), inhibitor of apoptosis proteins (IAPs), and MDM2 [43].

The diversity of E3 ligases provides opportunities for tissue-specific degradation and selective therapeutic targeting. Ongoing research aims to expand the repertoire of druggable E3 ligases to improve degrader efficacy and broaden therapeutic applications [44].

3.3 Proteasomal Degradation Mechanism



The 26S proteasome is a large ATP-dependent proteolytic complex responsible for degrading ubiquitinated proteins. It consists of a 20S catalytic core particle flanked by one or two 19S regulatory particles that recognize polyubiquitinated substrates [45].

Once a target protein is polyubiquitinated, the 19S regulatory particle binds the ubiquitin chain and initiates substrate processing. The protein is unfolded and translocated into the 20S catalytic chamber, where proteolytic enzymes degrade it into small peptide fragments.

Ubiquitin molecules are simultaneously removed and recycled for subsequent degradation cycles [46].

Proteasomal degradation is highly efficient and selective, making it an attractive pathway for therapeutic intervention. Most PROTACs and molecular glues exploit this mechanism to eliminate intracellular proteins involved in cancer, inflammation, and neurodegenerative diseases [47].

A significant advantage of proteasome-mediated degradation is its catalytic nature. A single degrader molecule can induce the degradation of multiple copies of a target protein, resulting in sustained biological effects even at relatively low concentrations [48].

3.4 Lysosome-Mediated Protein Degradation

Lysosomes represent an alternative degradation pathway capable of processing extracellular proteins, membrane proteins, large protein complexes, and aggregated proteins that may not be suitable substrates for proteasomal degradation [49].

Lysosomal degradation occurs through several mechanisms, including macroautophagy, microautophagy, and chaperone-mediated autophagy. In macroautophagy, cellular components are enclosed within double-membrane vesicles called autophagosomes, which subsequently fuse with lysosomes where degradation occurs [50].

Modern degrader technologies have been developed to exploit lysosomal pathways. LYTACs target extracellular and membrane-associated proteins for lysosomal degradation by engaging lysosome-shuttling receptors. AUTACs utilize selective autophagy mechanisms to eliminate intracellular proteins and damaged organelles, whereas ATTECs directly tether target proteins to autophagosomes for degradation [51].

These lysosome-based approaches significantly expand the range of therapeutic targets beyond those accessible through UPS-mediated degradation, opening new possibilities for treating neurodegenerative disorders and protein aggregation diseases [52].

3.5 Selectivity and Catalytic Mechanism of Protein Elimination

One of the defining features of targeted protein elimination is its remarkable selectivity. Unlike traditional inhibitors that require continuous binding to block protein function, degraders act by transiently recruiting degradation machinery to the target protein. This event-driven mechanism allows highly selective elimination while minimizing off-target interactions [53].

Selectivity is achieved through precise molecular recognition of both the target protein and the recruited E3 ligase or lysosomal receptor. The formation of stable ternary complexes is often critical for efficient degradation. Structural and biophysical studies have shown that cooperative interactions within these complexes strongly influence degradation efficiency and target specificity [54].

Another important characteristic of TPE is its catalytic mode of action. Following degradation of the target protein, the degrader molecule is released and can participate in additional degradation cycles. Consequently, substoichiometric concentrations of degraders can produce profound biological effects, distinguishing them from occupancy-driven inhibitors [55].

The catalytic nature of TPE may also help overcome drug resistance caused by target overexpression or mutation. Since degraders physically remove proteins from cells, they can eliminate both enzymatic and scaffolding functions, providing broader therapeutic benefits than conventional inhibitors [56].

Collectively, these mechanisms form the foundation of targeted protein elimination and explain its growing importance as a next-generation therapeutic strategy capable of addressing previously inaccessible disease targets [57].

4. MAJOR MODALITIES OF TARGETED PROTEIN ELIMINATION

The rapid advancement of targeted protein elimination has resulted in the development of multiple degradation platforms that exploit different cellular pathways for selective protein removal. These modalities differ in structure, mechanism of action, target scope, and therapeutic applications. Collectively, they have expanded the range of druggable targets and opened new opportunities for treating diseases that were previously difficult to address using conventional therapeutic approaches [58,59].

4.1 Proteolysis-Targeting Chimeras (PROTACs)

Proteolysis-targeting chimeras (PROTACs) are the most extensively studied and clinically advanced class of targeted protein degraders. PROTACs are heterobifunctional molecules composed of three components: a ligand that binds the target protein, a ligand that recruits an E3 ubiquitin ligase, and a linker connecting the two ligands [60].

Upon binding both the target protein and the E3 ligase, PROTACs facilitate the formation of a ternary complex that brings the target protein into close proximity with the ubiquitination machinery. This interaction promotes polyubiquitination of the target protein, leading to its recognition and degradation by the proteasome [61].

PROTACs offer several advantages over conventional inhibitors. They function catalytically, require only transient target engagement, and can eliminate both enzymatic and scaffolding functions of proteins. Furthermore, PROTACs can target proteins previously considered undruggable due to the absence of active sites suitable for inhibition [62].

Several PROTACs have entered clinical trials for the treatment of cancer, including androgen receptor degraders and estrogen receptor degraders. Early clinical data have demonstrated promising efficacy and acceptable safety profiles, highlighting the therapeutic potential of this technology [63].

Despite these advances, challenges remain, including large molecular size, limited oral bioavailability, and optimization of pharmacokinetic properties. Ongoing medicinal chemistry efforts aim to overcome these limitations and improve clinical performance [64].

4.2 Molecular Glues

Molecular glues are small molecules that induce or stabilize interactions between a target protein and an E3 ubiquitin ligase, resulting in target degradation. Unlike PROTACs, molecular glues are monovalent compounds and do not require separate ligands connected by a linker [65].

The discovery of immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide provided the first evidence of molecular glue-mediated degradation. These compounds bind cereblon (CRBN), altering its substrate specificity and promoting degradation of transcription factors such as IKZF1 and IKZF3 [66].

Molecular glues possess several advantages, including smaller molecular weight, improved cell permeability, and favorable pharmacokinetic properties compared with PROTACs. However, their discovery has traditionally relied on serendipity, making rational design more challenging [67].

Recent advances in structural biology and computational drug discovery are facilitating the identification of novel molecular glues and expanding their therapeutic applications in oncology, immunology, and neurodegenerative diseases [68].

4.3 Lysosome-Targeting Chimeras (LYTACs)

Lysosome-targeting chimeras (LYTACs) were developed to overcome the limitations of proteasome-based degradation systems. Unlike PROTACs, which primarily target intracellular proteins, LYTACs can eliminate extracellular proteins and membrane-associated proteins [69].

LYTACs consist of a target-binding moiety linked to a ligand that binds lysosome-shuttling receptors such as the cation-independent mannose-6-phosphate receptor (CI-M6PR). Upon receptor engagement, the target protein is internalized and transported to lysosomes for degradation [70].

This technology significantly broadens the scope of targeted protein elimination by enabling degradation of secreted proteins, cell-surface receptors, and extracellular signaling molecules. Potential applications include cancer, inflammatory disorders, and autoimmune diseases [71].

Ongoing research focuses on improving tissue specificity and optimizing receptor-mediated delivery to enhance therapeutic efficacy while minimizing off-target effects [72].

4.4 Autophagy-Targeting Chimeras (AUTACs)

Autophagy-targeting chimeras (AUTACs) exploit the autophagy–lysosome pathway for selective degradation of intracellular proteins and organelles. AUTACs contain a targetbinding ligand linked to a degradation tag that induces selective autophagy [73].

Following target recognition, AUTACs promote K63-linked ubiquitination, triggering autophagic sequestration of the target. The cargo is subsequently incorporated into autophagosomes and degraded after fusion with lysosomes [74].

A unique advantage of AUTACs is their ability to eliminate not only proteins but also damaged organelles such as mitochondria. This capability makes them attractive candidates for treating neurodegenerative diseases and disorders associated with mitochondrial dysfunction [75].

Although still in early stages of development, AUTAC technology has demonstrated promising preclinical results and continues to attract significant interest as a complementary degradation strategy [76].

4.5 Autophagosome-Tethering Compounds (ATTECs)


Autophagosome-tethering compounds (ATTECs) represent another autophagy-based degradation platform. These small molecules simultaneously bind a target protein and LC3, a key autophagosomal protein, thereby tethering the target directly to autophagosomes for degradation [77].

Unlike AUTACs, which depend on ubiquitination signals, ATTECs facilitate direct recruitment of target proteins to autophagic machinery. This mechanism has proven particularly effective in degrading aggregation-prone proteins implicated in neurodegenerative diseases [78].

Preclinical studies have demonstrated successful elimination of mutant huntingtin protein, a major pathogenic factor in Huntington's disease. These findings suggest that ATTECs may offer a promising therapeutic strategy for protein aggregation disorders [79].

Further optimization is needed to improve selectivity, bioavailability, and translational potential before widespread clinical application can be achieved [80].

RIBOTACs contain an RNA-binding module linked to a ribonuclease-recruiting moiety. Upon binding the target RNA, endogenous RNases are recruited, resulting in selective RNA cleavage and degradation [81].



This technology offers a novel strategy for targeting pathogenic RNAs involved in viral infections, cancer, and genetic disorders. By eliminating RNA before protein synthesis occurs, RIBOTACs provide an additional layer of therapeutic intervention [82].

Although still in early development, RNA-targeting degradation technologies have the potential to complement protein-targeted approaches and expand the scope of precision medicine [83].

5. DESIGN AND DEVELOPMENT OF PROTEIN DEGRADERS

The successful translation of targeted protein elimination technologies from basic research to clinical application depends on the rational design and optimization of protein degraders. Unlike conventional small-molecule inhibitors, degraders must simultaneously engage a target protein and components of the cellular degradation machinery. Therefore, the development process requires careful consideration of multiple factors, including target selection, recruitment of degradation pathways, molecular architecture, pharmacokinetic behavior, and therapeutic efficacy. Advances in medicinal chemistry, structural biology, computational modeling, and chemical biology have significantly accelerated the development of highly selective and potent degraders for a wide range of diseases [84].

5.1 Target Selection

Target selection represents one of the most critical steps in degrader development. The ideal target is a disease-associated protein whose elimination produces a measurable therapeutic benefit. Many proteins involved in cancer, neurodegenerative diseases, autoimmune disorders, and viral infections have emerged as attractive candidates because of their central role in disease progression [85].

Unlike traditional drug discovery approaches that require a well-defined active site for inhibition, targeted protein elimination can act on proteins that lack enzymatic activity or possess structurally challenging surfaces. This capability greatly expands the druggable proteome. Transcription factors, scaffolding proteins, regulatory proteins, and protein complexes that were once considered inaccessible to conventional therapeutics can now be targeted through degradation strategies.

Another important consideration is protein turnover rate. Proteins with slow natural turnover often represent attractive targets because degradation can produce prolonged biological effects. In contrast, rapidly synthesized proteins may require sustained degrader exposure to maintain therapeutic efficacy. Researchers also evaluate protein expression patterns across tissues to minimize toxicity and maximize disease specificity.

Target validation studies using genetic knockdown, CRISPR-based editing, and RNA interference technologies frequently provide valuable information regarding the consequences of protein elimination. These studies help determine whether degradation is likely to produce beneficial outcomes without causing unacceptable adverse effects .

5.2 E3 Ligase Recruitment

The recruitment of E3 ubiquitin ligases is a fundamental component of many targeted protein degradation platforms. E3 ligases are responsible for recognizing substrate proteins and catalyzing ubiquitin transfer, making them key determinants of degradation efficiency and selectivity.

Although hundreds of E3 ligases exist in human cells, only a limited number have been extensively exploited for degrader development. Cereblon (CRBN) and von Hippel–Lindau (VHL) remain the most widely utilized because their structures, ligands, and biological functions are well characterized. The availability of high-affinity ligands for these ligases has facilitated the design of numerous PROTAC molecules currently undergoing preclinical and clinical evaluation.

The choice of E3 ligase can strongly influence degradation outcomes. Factors such as tissue distribution, expression level, subcellular localization, and ubiquitination efficiency contribute to degrader performance. Different E3 ligases may exhibit varying abilities to degrade the same target protein, highlighting the importance of selecting appropriate ligase recruiters during the design process.

Recent research has focused on expanding the E3 ligase toolbox by identifying novel ligases that can be recruited selectively in specific tissues or disease contexts. This approach may improve therapeutic precision and reduce off-target toxicity. The discovery of additional ligase ligands is expected to significantly broaden the scope of targeted protein elimination in the future.

5.3 Linker Design and Optimization

For bifunctional degraders such as PROTACs, the linker plays a crucial role in determining biological activity. The linker connects the target-binding ligand to the E3 ligase ligand and directly influences ternary complex formation, degradation efficiency, selectivity, and pharmacokinetic properties.

Linker length is particularly important because it determines the spatial orientation of the target protein and E3 ligase. Excessively short linkers may prevent productive interactions, whereas overly long linkers can reduce degradation efficiency by increasing molecular flexibility. Achieving the optimal balance often requires extensive experimental optimization.

Linker composition also affects degrader performance. Flexible polyethylene glycol (PEG) based linkers can improve solubility, while rigid aromatic linkers may enhance selectivity by promoting favorable protein–protein interactions. In many cases, subtle modifications in linker structure can dramatically alter degradation potency.

Structural biology techniques such as X-ray crystallography and cryo-electron microscopy have improved understanding of ternary complex architecture, enabling more rational linker design. Computational modeling and molecular dynamics simulations are increasingly used to predict productive conformations and guide optimization efforts.

The development of linker technologies remains an active area of research because improved linker design can enhance cellular permeability, tissue distribution, metabolic stability, and overall therapeutic efficacy.

5.4 Pharmacokinetic and Pharmacodynamic Considerations

The pharmacokinetic behavior of degraders presents unique challenges compared with traditional small-molecule drugs. Many degraders possess relatively large molecular weights and increased structural complexity, which can negatively affect absorption, distribution, metabolism, and excretion.

Achieving adequate oral bioavailability remains a major objective in degrader development. Large bifunctional molecules often violate conventional drug-likeness rules, leading to reduced membrane permeability and poor

gastrointestinal absorption. Medicinal chemists employ various strategies such as molecular rigidification, linker optimization, and prodrug approaches to improve pharmacokinetic properties.

Distribution within target tissues is another critical factor. Effective degraders must reach sufficient intracellular concentrations while maintaining selectivity for disease-associated proteins. Tissue-specific degradation may be particularly important for minimizing toxicity and improving therapeutic outcomes.

Pharmacodynamic evaluation differs from traditional inhibitor-based approaches because degradation rather than occupancy determines biological activity. Consequently, researchers often monitor protein depletion levels, duration of degradation, and recovery kinetics as primary indicators of efficacy.

An important advantage of targeted protein elimination is the possibility of sustained pharmacological effects even after plasma drug concentrations decline. Because degraders can catalytically remove target proteins, transient exposure may produce prolonged biological responses, potentially reducing dosing frequency and improving patient compliance.

5.5 Drug Discovery Approaches and Emerging Technologies

Modern degrader discovery integrates multiple scientific disciplines to accelerate therapeutic development. High-throughput screening platforms are widely used to identify novel target ligands, E3 ligase binders, and degradation-inducing molecules. These approaches allow rapid evaluation of thousands of compounds for degradation activity.

Structure-based drug design has become increasingly important in degrader development. Detailed knowledge of protein structures enables rational optimization of target engagement, ternary complex stability, and degradation efficiency. Advances in cryo-electron microscopy and computational structural prediction have provided unprecedented insights into degrader mechanisms.

Artificial intelligence (AI) and machine learning technologies are emerging as powerful tools for predicting degrader activity and guiding molecular design. These approaches can analyze large datasets to identify favorable molecular features, optimize linker properties, and predict pharmacokinetic behavior. AI-driven drug discovery is expected to substantially reduce development timelines and costs.

Another promising area involves tissue-specific and conditional degraders capable of selectively eliminating proteins in particular cell types or disease environments. Such technologies may improve therapeutic precision and reduce systemic toxicity. Researchers are also exploring combinations of degrader therapies with conventional drugs, immunotherapies, and gene-editing approaches to enhance clinical outcomes.

The rapid evolution of targeted protein elimination technologies continues to transform drug discovery. Ongoing innovations in chemistry, biology, computational science, and clinical pharmacology are expected to generate next-generation degraders with improved efficacy, safety, and therapeutic versatility. As understanding of degradation mechanisms expands, targeted protein elimination is likely to become an increasingly important component of precision medicine and future therapeutic development.

6. APPLICATIONS OF TARGETED PROTEIN ELIMINATION

Targeted Protein Elimination (TPE) has emerged as one of the most promising therapeutic innovations in modern drug discovery. By enabling the selective removal of disease-causing proteins, TPE offers advantages that extend beyond conventional inhibition strategies. The ability to degrade proteins rather than simply block their activity allows the elimination of both catalytic and non-catalytic functions, resulting in more comprehensive therapeutic effects. As a consequence, TPE technologies have been investigated across a wide range of disease areas, including cancer, neurodegenerative disorders, inflammatory diseases, infectious diseases, and metabolic disorders. Continuous advances in degrader design have significantly expanded the

potential applications of this therapeutic platform and have established targeted protein elimination as a versatile approach for addressing complex medical challenges .

6.1 Cancer Therapy

Cancer remains the most extensively studied application of targeted protein elimination. Tumor development and progression are frequently driven by abnormal protein expression, oncogenic mutations, dysregulated signaling pathways, and resistance mechanisms that limit the effectiveness of traditional therapies. TPE provides an opportunity to directly eliminate these pathogenic proteins and disrupt cancer-promoting cellular networks.

Many oncogenic proteins serve functions beyond enzymatic activity, including scaffolding, transcriptional regulation, and protein-protein interactions. Conventional inhibitors often fail to fully suppress these functions. In contrast, targeted degradation removes the entire protein, producing a more complete therapeutic response.

Particular attention has been directed toward proteins such as androgen receptors (AR), estrogen receptors (ER), bromodomain-containing proteins (BET proteins), BCL-2 family members, cyclin-dependent kinases (CDKs), and mutant kinases involved in tumor progression. Degradation molecules targeting these proteins have demonstrated potent antitumor activity in preclinical studies and clinical trials.

In prostate cancer, androgen receptor degraders have shown encouraging results, especially in patients who develop resistance to androgen receptor inhibitors. Similarly, estrogen receptor degraders are being investigated for hormone receptor-positive breast cancer and have demonstrated the ability to overcome resistance associated with endocrine therapies.

Another important advantage of TPE in oncology is its ability to address drug resistance. Cancer cells frequently acquire mutations that reduce inhibitor binding while preserving protein function. Because degraders eliminate the target protein itself, they may remain effective even when resistance mutations emerge. This capability has generated substantial interest in using degraders against previously resistant cancers.

Additionally, TPE has enabled the targeting of transcription factors and other proteins that were historically considered undruggable. Such advances significantly expand therapeutic opportunities and may lead to the development of treatments for cancers lacking effective targeted therapies .

6.2 Neurodegenerative Disorders

Neurodegenerative diseases are characterized by progressive neuronal loss and accumulation of toxic protein aggregates within the nervous system. Disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) involve abnormal protein folding, aggregation, and impaired protein clearance mechanisms.

Targeted protein elimination offers a unique strategy for addressing the underlying causes of these disorders. Rather than merely alleviating symptoms, degraders have the potential to remove disease-causing proteins directly from affected cells.

In Alzheimer's disease, pathological accumulation of amyloid-beta peptides and tau protein contributes to neuronal dysfunction and cognitive decline. Targeted degradation approaches are being explored to reduce intracellular tau levels and limit neurotoxicity. Removal of tau aggregates may slow disease progression and preserve neuronal function.

Parkinson's disease is associated with aggregation of α -synuclein, which forms toxic intracellular inclusions known as Lewy bodies. Several degradation technologies are under investigation to selectively eliminate α -synuclein and prevent further neuronal damage.

Huntington's disease results from expansion mutations in the huntingtin gene that generate toxic mutant huntingtin protein. Autophagy-based degradation platforms, particularly ATTECs, have shown promising results in selectively reducing mutant huntingtin levels while preserving normal protein function.

The ability of lysosome-targeting degraders and autophagy-based technologies to eliminate large protein aggregates represents a major advantage for neurodegenerative applications. Since aggregated proteins are often poor substrates for proteasomal degradation, autophagic pathways provide an alternative mechanism for effective clearance.

Although challenges related to blood–brain barrier penetration remain significant, ongoing research aims to improve central nervous system delivery and enhance therapeutic efficacy. These developments position TPE as a promising strategy for treating currently incurable neurodegenerative disorders .

6.3 Inflammatory and Autoimmune Diseases

Inflammatory and autoimmune diseases arise from dysregulated immune responses that result in chronic tissue damage and systemic inflammation. Many of these conditions are driven by aberrant signaling proteins, transcription factors, cytokines, and immune regulatory molecules.

Targeted protein elimination offers opportunities to selectively remove proteins that contribute to pathological immune activation. Unlike conventional immunosuppressive therapies that broadly suppress immune function, degraders can potentially provide more precise modulation of disease-associated pathways.

Proteins involved in inflammatory signaling cascades, such as nuclear factor-kappa B (NFκB), Janus kinases (JAKs), signal transducers and activators of transcription (STATs), and various cytokine receptors, represent attractive targets for degradation. Elimination of these proteins may reduce inflammatory responses while minimizing systemic toxicity.

Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, and multiple sclerosis may benefit from degrader-based approaches. Selective degradation of immune regulators could suppress disease activity while preserving protective immune functions.

Another promising application involves degradation of pathogenic antibodies or extracellular inflammatory mediators using lysosome-targeting technologies. Such approaches could provide new treatment options for diseases driven by circulating proteins and immune complexes.

As understanding of immune signaling networks continues to improve, targeted protein elimination may become an increasingly important tool for precision immunomodulation and treatment of chronic inflammatory disorders .

6.4 Infectious Diseases

The emergence of antimicrobial resistance and recurrent viral outbreaks highlights the need for innovative therapeutic strategies in infectious diseases. Targeted protein elimination has the potential to address this challenge by targeting either pathogen-derived proteins or host factors required for infection.

Many viruses depend on specific host proteins for replication, assembly, and transmission. Degradation of these host factors can interrupt the viral life cycle and reduce the likelihood of resistance development. Because host proteins mutate less rapidly than viral proteins, host-targeted degradation may provide durable therapeutic benefits.

Researchers have investigated degrader approaches against proteins associated with infections caused by human immunodeficiency virus (HIV), hepatitis viruses, influenza viruses, and coronaviruses. Selective elimination of viral proteins or critical host cofactors may inhibit viral replication and reduce disease severity.

In bacterial infections, degradation of proteins involved in virulence, toxin production, or host-pathogen interactions could provide alternative treatment strategies. Such approaches may complement traditional antimicrobial therapies and help address increasing antimicrobial resistance.

The flexibility of TPE platforms enables rapid adaptation to emerging pathogens, making targeted degradation an attractive strategy for future infectious disease preparedness and response efforts.

6.5 Cardiovascular and Metabolic Disorders

Cardiovascular and metabolic diseases remain leading causes of morbidity and mortality worldwide. Dysregulation of signaling pathways, lipid metabolism, inflammation, and cellular stress responses contributes significantly to disease development.

Targeted protein elimination has begun to attract attention as a strategy for modulating proteins involved in these pathological processes. Proteins regulating cholesterol metabolism, lipid transport, insulin signaling, and inflammatory pathways represent promising therapeutic targets.

In cardiovascular disease, degradation of proteins associated with atherosclerosis, vascular inflammation, and cardiac remodeling may provide novel approaches for disease prevention and treatment. Selective elimination of pathogenic signaling molecules could reduce vascular damage and improve cardiovascular outcomes.

Metabolic disorders such as obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver disease involve complex networks of regulatory proteins. Degradation technologies may offer opportunities to modulate these pathways more effectively than conventional inhibitors.

Additionally, targeted elimination of proteins associated with fibrosis and chronic inflammation could help prevent organ damage in advanced metabolic diseases. As research progresses, TPE may contribute to the development of highly selective therapies capable of addressing the molecular drivers of cardiometabolic disorders.

Overall, the expanding application of targeted protein elimination across multiple therapeutic areas highlights its transformative potential. By enabling selective and efficient removal of disease-causing proteins, TPE is poised to become a cornerstone of future precision medicine and next-generation drug development.

7. CLINICAL PROGRESS OF TARGETED PROTEIN ELIMINATION

The transition of targeted protein elimination (TPE) from a conceptual drug discovery strategy to a clinically validated therapeutic platform represents one of the most significant achievements in modern pharmacology. Over the past decade, advances in medicinal chemistry, structural biology, and molecular pharmacology have enabled the development of degraders with improved potency, selectivity, and pharmacokinetic properties. As a result, numerous degrader molecules have entered clinical evaluation, particularly in oncology, where abnormal protein expression and resistance to conventional therapies remain major challenges.

The growing number of clinical candidates reflects increasing confidence in the therapeutic potential of targeted protein degradation. Early clinical studies have demonstrated that degraders can achieve substantial target protein depletion in patients while maintaining manageable safety profiles. Importantly, many of these molecules have shown activity against disease-associated proteins that were previously difficult to inhibit effectively using traditional approaches.

7.1 Evolution of Clinical Development

The earliest generations of targeted protein degraders were primarily designed as research tools for studying protein function. However, improvements in molecular design and optimization rapidly transformed these compounds into viable therapeutic candidates. The development of high-affinity ligands for E3 ligases such

as cereblon (CRBN) and von Hippel–Lindau (VHL) significantly accelerated this process by enabling the creation of potent and selective degraders.

Clinical development has largely focused on oncology because cancer cells frequently depend on specific proteins for survival and proliferation. Targeted degradation offers several advantages in this setting, including elimination of mutant proteins, suppression of resistance mechanisms, and removal of proteins that possess both enzymatic and structural functions.

As clinical experience has expanded, researchers have gained valuable insights into degrader pharmacology, target engagement, dose optimization, and biomarker development. These lessons are expected to facilitate future clinical programs across multiple therapeutic areas.

7.2 ARV-110 (Bavdegalutamide)

ARV-110, also known as bavdegalutamide, was among the first PROTAC-based therapeutics to enter human clinical trials. Developed for metastatic castration-resistant prostate cancer (mCRPC), ARV-110 targets and degrades the androgen receptor (AR), a critical driver of prostate cancer progression.

Resistance to conventional androgen receptor inhibitors frequently develops through receptor overexpression, mutations, or activation of alternative signaling pathways. Because ARV-110 eliminates the receptor itself rather than merely blocking its activity, it has the potential to overcome several forms of treatment resistance.

Clinical studies have demonstrated substantial degradation of androgen receptor proteins and encouraging antitumor activity in selected patient populations. Responses have been particularly notable in patients harboring specific androgen receptor mutations associated with resistance to standard therapies.

The clinical experience gained from ARV-110 has provided important proof-of-concept evidence that targeted protein degradation can be successfully translated into human therapeutics. It has also established critical benchmarks for future degrader development programs.

7.3 ARV-471 (Vepdegestrant)

ARV-471, now widely known as vepdegestrant, is a selective estrogen receptor degrader developed for estrogen receptor-positive (ER+) breast cancer. Estrogen receptor signaling plays a central role in the growth and survival of many breast cancers, making it an attractive therapeutic target.

Traditional endocrine therapies often encounter resistance due to receptor mutations, altered signaling pathways, or adaptive cellular responses. Vepdegestrant was designed to overcome these limitations by inducing robust degradation of estrogen receptor proteins.

Clinical studies have demonstrated significant receptor depletion and promising antitumor activity in patients with advanced breast cancer. The ability of vepdegestrant to reduce estrogen receptor levels more effectively than some existing endocrine therapies has generated considerable interest within the oncology community.

The success of ARV-471 further validates the concept that complete removal of oncogenic proteins may provide superior therapeutic benefits compared with simple inhibition. Ongoing trials continue to evaluate its efficacy both as a monotherapy and in combination with other anticancer agents.

7.4 CFT7455

CFT7455 is a cereblon-based degrader developed primarily for hematological malignancies such as multiple myeloma and non-Hodgkin lymphoma. The molecule promotes degradation of proteins involved in cancer cell survival and proliferation, thereby disrupting critical oncogenic pathways.

One of the key advantages of CFT7455 is its ability to induce potent degradation of transcription factors that are essential for malignant cell growth. Since transcription factors have traditionally been difficult to target using conventional small molecules, degradation-based strategies provide a unique therapeutic opportunity.

Early clinical investigations have shown encouraging pharmacodynamic effects, including substantial target protein reduction and evidence of antitumor activity. These findings support continued evaluation of CFT7455 as a potential treatment option for patients with relapsed or refractory hematological cancers.

The development of CFT7455 highlights the growing ability of targeted protein degradation technologies to address previously inaccessible disease targets.

7.5 NX-5948

NX-5948 represents another important advancement in clinical-stage protein degradation therapeutics. This molecule was designed to target Bruton's tyrosine kinase (BTK), a protein that plays a critical role in B-cell malignancies and immune signaling pathways.

Conventional BTK inhibitors have transformed the treatment of several hematological cancers; however, resistance frequently develops due to mutations that impair drug binding. NX-5948 addresses this challenge by promoting degradation of BTK rather than simply inhibiting its enzymatic activity.

Preclinical studies demonstrated potent degradation of both wild-type and mutant BTK proteins, including variants associated with resistance to approved BTK inhibitors. These findings provided strong rationale for clinical development.

Early clinical evaluations suggest that BTK degradation may offer a valuable therapeutic strategy for patients who no longer respond to traditional BTK-targeted therapies. Continued clinical investigation will clarify the long-term efficacy and safety of this approach.

7.6 Emerging Clinical Candidates

Beyond the well-known degraders currently undergoing clinical evaluation, numerous additional candidates are advancing through preclinical and early clinical development. These molecules target a broad range of proteins involved in cancer, inflammation, neurodegeneration, and immune regulation.

Researchers are increasingly exploring degraders directed against transcription factors, signaling adaptors, epigenetic regulators, and scaffold proteins. Such targets have historically been difficult to inhibit using conventional pharmacological approaches but may be effectively addressed through targeted degradation.

Another major area of interest involves tissue-specific degraders capable of selectively eliminating proteins within particular organs or cell populations. This strategy may improve therapeutic precision while reducing systemic toxicity.

Lysosome-targeting technologies such as LYTACs, AUTACs, and ATTECs are also progressing toward clinical translation. These approaches may extend targeted degradation beyond intracellular proteins and enable elimination of extracellular proteins, membrane proteins, and protein aggregates associated with neurodegenerative diseases.

Advances in computational drug design, artificial intelligence, and structural biology are expected to accelerate the identification of novel degraders and improve their clinical performance. Consequently, the number of clinical candidates is anticipated to increase substantially over the coming years.

7.7 Current Challenges in Clinical Translation

Despite impressive progress, several challenges remain before targeted protein elimination achieves widespread clinical adoption. Optimization of oral bioavailability, tissue distribution, metabolic stability, and long-term safety continues to be a major focus of research.

Another important consideration involves identifying predictive biomarkers that can help select patients most likely to benefit from degrader therapies. Personalized treatment strategies based on molecular profiling may enhance therapeutic outcomes and maximize clinical success.

Potential resistance mechanisms also require careful investigation. Although degraders may overcome many forms of resistance associated with traditional inhibitors, alterations in E3 ligase expression, ubiquitination pathways, or protein degradation machinery could influence treatment response.

Addressing these challenges will be critical for ensuring the long-term success of targeted protein elimination as a therapeutic platform.

8. CONCLUSION

Targeted Protein Elimination (TPE) represents a major advancement in modern drug discovery and therapeutic development. Unlike conventional treatment strategies that primarily inhibit protein function, TPE enables the selective removal of disease-causing proteins by utilizing the cell's natural degradation machinery. This innovative approach has expanded the scope of therapeutic intervention, allowing researchers to target proteins that were previously considered difficult or impossible to drug using traditional methods.

The emergence of multiple degradation technologies, including PROTACs, molecular glues, LYTACs, AUTACs, ATTECs, AbTACs, and RIBOTACs, has significantly broadened the applicability of targeted protein elimination across diverse disease areas. These platforms have demonstrated promising potential in oncology, neurodegenerative disorders, autoimmune diseases, infectious diseases, and metabolic conditions. Their ability to eliminate both enzymatic and non-enzymatic protein functions offers distinct advantages over conventional inhibitors and may help overcome challenges such as drug resistance and target inaccessibility.

Recent clinical progress has validated the feasibility of protein degradation as a therapeutic strategy, with several degrader molecules advancing through clinical trials and demonstrating encouraging efficacy and safety profiles. These developments highlight the growing importance of TPE as a next-generation therapeutic platform with the potential to transform patient care.

Despite remarkable achievements, challenges related to pharmacokinetics, tissue-specific delivery, long-term safety, and resistance mechanisms remain areas of active investigation. Continued advances in medicinal chemistry, structural biology, computational modeling, and artificial intelligence are expected to accelerate the discovery and optimization of more effective degraders.

Overall, targeted protein elimination has the potential to redefine the future of precision medicine by providing innovative solutions for previously intractable diseases. As research continues to evolve, TPE is expected to play an increasingly important role in the development of safer, more selective, and highly effective therapeutics for a wide range of human diseases.

9. REFERENCE:

1. Bondeson DP, Crews CM. Targeted protein degradation by small molecules. *Annu Rev Pharmacol Toxicol*. 2017;57:107–123.
2. Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. *Signal Transduct Target Ther*. 2019;4:64.

3. Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. *Nat Rev Drug Discov.* 2022;21(3):181–200.
4. Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. *Nat Rev Drug Discov.* 2019;18(12):949–963.
5. Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. *Proc Natl Acad Sci USA.* 2001;98(15):8554–8559.
6. Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov.* 2017;16(2):101–114.
7. Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. *Nature.* 2020;584:291–297.
8. Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. *Mol Cell.* 2019;76(5):797–810.
9. Pettersson M, Crews CM. PROteolysis TARgeting Chimeras (PROTACs): □ Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov.* 2017;16(2):101–114.
10. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. *Nat Chem Biol.* 2019;15(10):937–944.
11. Mullard A. Targeted protein degraders crowd into the clinic. *Nat Rev Drug Discov.* 2021;20(4):247–250.
12. Paiva SL, Crews CM. Targeted protein degradation: elements of PROTAC design. *Curr Opin Chem Biol.* 2019;50:111–119.
13. Bond MJ, Chu L, Nalawansa DA, Crews CM. Targeted degradation of oncogenic proteins. *Curr Opin Chem Biol.* 2020;57:1–8.
14. Dale B, Cheng M, Park KS, et al. Advancing targeted protein degradation for cancer therapy. *Nat Rev Cancer.* 2021;21(10):638–654.
15. Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. *Nature.* 2020;580(7803):329–338.
16. Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov.* 2017;16(2):101–114.
17. Burslem GM, Crews CM. Small-molecule modulation of protein homeostasis. *Chem Rev.* 2017;117(17):11269–11301.
18. Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. *Nat Rev Drug Discov.* 2019;18(12):949–963.
19. Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. *Signal Transduct Target Ther.* 2019;4:64.
20. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. *Science.* 2008;319(5865):916–919.
21. Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and aggregation diseases. *Trends Cell Biol.* 2014;24(9):506–514.
22. Kaushik S, Cuervo AM. Proteostasis and aging. *Nat Med.* 2015;21(12):1406–1415.

- 23.Labbadia J, Morimoto RI. The biology of proteostasis in aging and disease. *Annu Rev Biochem.* 2015;84:435–464.
- 24.Ciechanover A. The ubiquitin–proteasome proteolytic pathway. *Cell.* 1994;79(1):13–21.
- 25.Hershko A, Ciechanover A. The ubiquitin system. *Annu Rev Biochem.* 1998;67:425–479.
- 26.Collins GA, Goldberg AL. The logic of the 26S proteasome. *Cell.* 2017;169(5):792–806.
- 27.Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol.* 2015;11(8):611–617.
- 28.Pettersson M, Crews CM. PROteolysis-targeting chimeras (PROTACs). *Drug Discov Today Technol.* 2019;31:15–27.
- 29.Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. *Nat Chem Biol.* 2019;15(10):937–944.
- 30.Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome. *Nat Rev Mol Cell Biol.* 2013;14(5):283–296.
- 31.Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimeras for degradation of extracellular proteins. *Nature.* 2020;584(7820):291–297.
- 32.Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. *Cell.* 2011;147(4):728–741.
- 33.Galluzzi L, Baehrecke EH, Ballabio A, et al. Molecular definitions of autophagy and related processes. *EMBO J.* 2017;36(13):1811–1836.
- 34.Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. *Mol Cell.* 2019;76(5):797–810.
- 35.Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant huntingtin by ATTEC. *Nat Chem Biol.* 2019;15(7):743–751.
- 36.Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. *Nature.* 2020;580(7803):329–338.
- 37.Banks M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. *Nat Rev Drug Discov.* 2022;21(3):181–200.
- 38.Pickart CM. Mechanisms underlying ubiquitination. *Annu Rev Biochem.* 2001;70:503–533.
- 39.Komander D, Rape M. The ubiquitin code. *Annu Rev Biochem.* 2012;81:203–229.
- 40.Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol.* 2015;11(8):611–617.
- 41.Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes. *Nat Rev Mol Cell Biol.* 2009;10(5):319–331.
- 42.Stewart MD, Ritterhoff T, Klevit RE, Brzovic PS. E2 enzymes: more than just middle men. *Cell Res.* 2016;26(4):423–440.
- 43.Nalawansa DA, Crews CM. PROTACs: an emerging therapeutic modality. *Cell Chem Biol.* 2020;27(8):998–1014.
- 44.Farnaby W, Koegl M, Roy MJ, et al. BAF complex vulnerabilities in cancer demonstrated via chemical protein degradation. *Nat Chem Biol.* 2019;15(7):672–680.

45. Collins GA, Goldberg AL. The logic of the 26S proteasome. *Cell*. 2017;169(5):792–806.
46. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu Rev Biochem*. 2009;78:477–513.
47. Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov*. 2017;16(2):101–114.
48. Pettersson M, Crews CM. PROteolysis-targeting chimeras (PROTACs): Past, present and future. *Drug Discov Today Technol*. 2019;31:15–27.
49. Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. *Nat Rev Mol Cell Biol*. 2020;21(2):101–118.
50. Mizushima N, Levine B. Autophagy in human diseases. *N Engl J Med*. 2020;383(16):1564–1576.
51. Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimeras for degradation of extracellular proteins. *Nature*. 2020;584(7820):291–297.
52. Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. *Mol Cell*. 2019;76(5):797–810.
53. Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. *Nat Rev Drug Discov*. 2019;18(12):949–963.
54. Zorba A, Nguyen C, Xu Y, et al. Delineating the role of cooperativity in the design of potent PROTACs. *Proc Natl Acad Sci USA*. 2018;115(31):E7285–E7292.
54. Bond MJ, Chu L, Nalawansa DA, Crews CM. Targeted degradation of oncogenic proteins. *Curr Opin Chem Biol*. 2020;57:1–8.
55. Dale B, Cheng M, Park KS, et al. Advancing targeted protein degradation for cancer therapy. *Nat Rev Cancer*. 2021;21(10):638–654.
56. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. *Nat Chem Biol*. 2019;15(10):937–944.
57. Bökris M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. *Nat Rev Drug Discov*. 2022;21(3):181–200.
58. Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. *Nat Rev Drug Discov*. 2019;18(12):949–963.
59. Sakamoto KM, Kim KB, Kumagai A, et al. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. *Proc Natl Acad Sci USA*. 2001;98(15):8554–8559.
60. Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. *Nat Chem Biol*. 2015;11(8):611–617.
61. Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. *Nat Rev Drug Discov*. 2017;16(2):101–114.
62. Mullard A. Targeted protein degraders crowd into the clinic. *Nat Rev Drug Discov*. 2021;20(4):247–250.
63. Pettersson M, Crews CM. PROteolysis-targeting chimeras (PROTACs): Past, present and future. *Drug Discov Today Technol*. 2019;31:15–27.

64. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. *Nat Chem Biol.* 2019;15(10):937–944.
65. Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3. *Science.* 2014;343(6168):301–305.
66. St-Cyr DJ, Crews CM. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. *Cell Chem Biol.* 2023;30(5):570–584.
67. Mayor-Ruiz C, Jaeger MG, Bauer S, et al. Rational discovery of molecular glue degraders. *Nat Chem Biol.* 2020;16(11):1199–1207.
68. Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. *Nature.* 2020;584(7820):291–297.
69. Ahn G, Banik SM, Miller CL, et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. *Nat Chem Biol.* 2021;17(9):937–946.
70. Caianiello DF, Zhang M, Ray JD, et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. *Nat Chem Biol.* 2021;17(9):947–953.
71. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. *Cell.* 2020;181(1):102–114.
72. Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. *Mol Cell.* 2019;76(5):797–810.
73. Yamano K, Matsuda N, Tanaka K. The ubiquitin signal and autophagy. *Curr Opin Cell Biol.* 2016;39:1–9.
74. Pickles S, Vig P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. *Curr Biol.* 2018;28(4):R170–R185.
75. Ji CH, Kwon YT. Crosstalk and interplay between the ubiquitin–proteasome system and autophagy. *Mol Cells.* 2017;40(7):441–449.
76. Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant huntingtin by ATTEC. *Nat Chem Biol.* 2019;15(7):743–751.
77. Lu M, Liu T, Jiao Q, et al. Discovery of ATTEC molecules for targeted degradation through autophagy. *Autophagy.* 2021;17(8):2185–2200.
78. Rui YN, Xu Z, Patel B, et al. Huntingtin functions as a scaffold for selective macroautophagy. *Nat Cell Biol.* 2015;17(3):262–275.
79. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol.* 2018;19(6):349–364.
80. Cotton AD, Nguyen DP, Gramespacher JA, et al. Development of antibody-based PROTACs for targeted degradation. *Proc Natl Acad Sci USA.* 2021;118(45):e2107895118.
81. Marei H, Tsai WK, Kee YS. Antibody-mediated targeted protein degradation technologies. *Trends Pharmacol Sci.* 2022;43(4):267–281.
82. Mullard A. Targeted degradation moves beyond the proteasome. *Nat Rev Drug Discov.* 2021;20(9):657–659.
83. PJ, Lazar GA. Next generation antibody drugs. *Nat Rev Drug Discov.* 2018;17(3):197–223.

84. Costales MG, Childs-Disney JL, Haniff HS, Disney MD. How we think about targeting RNA with small molecules. *J Med Chem.* 2020;63(16):8880–8900.
85. Costales MG, Aikawa H, Li Y, et al. Small-molecule targeted recruitment of a nuclease to RNA. *J Am Chem Soc.* 2020;142(8):3696–3703.

Copyright & License:

© Authors retain the copyright of this article. This work is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), permitting unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.